Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SILTUXIMAB Cause Drug effective for unapproved indication? 23 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Drug effective for unapproved indication have been filed in association with SILTUXIMAB (Sylvant). This represents 4.9% of all adverse event reports for SILTUXIMAB.

23
Reports of Drug effective for unapproved indication with SILTUXIMAB
4.9%
of all SILTUXIMAB reports
0
Deaths
0
Hospitalizations

How Dangerous Is Drug effective for unapproved indication From SILTUXIMAB?

Of the 23 reports.

Is Drug effective for unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SILTUXIMAB. However, 23 reports have been filed with the FAERS database.

What Other Side Effects Does SILTUXIMAB Cause?

Off label use (96) Drug ineffective (72) Disease progression (32) Immune effector cell-associated neurotoxicity syndrome (28) Death (27) Cytokine release syndrome (26) Hypertension (24) Product use in unapproved indication (24) Cataract (19) Condition aggravated (19)

What Other Drugs Cause Drug effective for unapproved indication?

DICLOFENAC (6,550) ACETAMINOPHEN\ASPIRIN\CAFFEINE (3,300) ACETAMINOPHEN\IBUPROFEN (1,620) IBUPROFEN (1,530) RITUXIMAB (1,233) DIPHENHYDRAMINE\IBUPROFEN (864) TOFACITINIB (669) PREDNISONE (657) NAPROXEN (499) BEVACIZUMAB (461)

Which SILTUXIMAB Alternatives Have Lower Drug effective for unapproved indication Risk?

SILTUXIMAB vs SILVER SULFADIAZINE SILTUXIMAB vs SIMEPREVIR SILTUXIMAB vs SIMPONI SILTUXIMAB vs SIMVASTATIN SILTUXIMAB vs SINGULAIR

Related Pages

SILTUXIMAB Full Profile All Drug effective for unapproved indication Reports All Drugs Causing Drug effective for unapproved indication SILTUXIMAB Demographics